Genistein 80%90%95%98%M.F.C15 H10O5.CAS.NO:446-72-0,Daidzein 98%M.F.C15 H10O4.CAS.NO:486-66-8.soy isoflavone,Glycine max L.extract.soy isoflavones


Botanical Source:Soybeans,Glycine max, Glycine soja , Soya,Beans

Common Names&Synonyms:genistein, daidzein and glycetin,Da Dou.phytoestrogens,soy isoflavone products,soy isoflavone aglycones,soy phytoestrogens,Genistein mimics human estrogens

What is genistein?

Isoflavonoids are a group of diphenolic hormone-like compounds of dietary origin that are of great interest particularly because of their anti-carcinogenic potency, but also because of their association with other Western diseases like coronary heart disease.
These isoflavonoids are derived mainly from soy-protein products, while clover seeds and leaves are a rich source of Biochanin A and Formononetin.
Genistein precursors such as Genistin and Biochainin A are converted by the intestinal microflora to Genistein into gut.



Genistein mimics human estrogens:

In research collaborations with scientists in the Department of Medicinal Chemistry here at Ohio State, we are investigating the nature of these potentially conserved signaling and signal transduction pathways. So far evidence suggests possible parallels in apoptotic cell death, estrogen-like and interleukin signaling pathways.
Shown at left is the soybean isoflavone genistein (the small grey structure with red hydroxy groups) binding to the human estrogen receptor ER-Alfa.
Genistein is one of the most potent phytoestrogens. It mimics human estrogens by binding to both ER-Alfa and ER-Beta and has promising anti-breast cancer activity.
Genistein is also a central signal in soybean for the potentiation of defense responses. Interestingly, human estrogens such as estradiol also activate defense potentiation in soybean, possibly by acting as a genistein mimic.


Reference Link: Click for more Details


Estrogenic Effects of Genistein:

The phytoestrogen genistein is present naturally as several ?-glucosides, which are metabolized by intestinal microflora to genistein. Genistein, a planar molecule with an aromatic A ring, has a chemical structure similar to steroidal estrogens, and its ability to behave as an estrogen in various tissues has been widely described. Observations of phytoestrogens'''''''''''''''' estrogenic properties date back to the 1950s, when it was discovered that the diadezan metabolite equol was the compound responsible for reduced reproductive capacity in sheep grazing on clover. Subsequently, countless studies have been conducted to characterize the hormonal effects of phytoestrogens including genistein''''''''''''''''s estrogenic and presumed antiestrogenic properties.

Genistein has significant estrogenic properties in both in vitro and in vivo models. Genistein binds to the estrogen receptor (ER), although its binding affinity is several-fold weaker than that of estradiol. Genistein can also activate a number of estrogen-responsive genes in vitro, including pS2 and c-fos. Furthermore, when administered at low doses, genistein stimulates the growth of ER-positive (ER+) breast cancer cells. Findings in other tissue systems support the estrogenicity of genistein. For example, genistein is uterotrophic in a variety of species, resulting in impaired reproductive activity and increases in uterine wet weights. It is important to note that some studies have failed to see any effect of genistein on the uterus, including alterations in wet weight. Furthermore, findings with coumestrol, a more estrogenic phytoestrogen than genistein, indicate that although coumestrol increases uterine wet weights, it does not increase uterine DNA content or alter other indicators of more true estrogenic activity. Thus, an increase in uterine wet weight alone does not necessarily indicate that genistein has estrogenic properties.

In addition to directly binding to the ER, genistein may indirectly affect estrogenicity through inhibition of the cytochrome P450 enzyme CYP1A1. It has recently been shown that genistein is a noncompetitive inhibitor of the CYP1A1 enzyme, which apart from playing a role in the metabolism of carcinogens, is responsible for the metabolic degradation of 17Beta-estradiol. Thus, it is possible that genistein-mediated inhibition of estradiol degradation could result in higher levels of circulating estradiol and thus elevated ER activity.

Genistein has estrogenic effects on the hypothalamic/pituitary axis in ovariectomized Sprague-Dawley rats. Human studies indicate that high soy intake can disrupt the hypothalamic/pituitary/gonadal axis in premenopausal women similar to that seen in animal models. This perturbation is not seen in postmenopausal women, suggesting a differential effect of soy/genistein on pre- and postmenopausal women. Finally, genistein may exert beneficial effects on bone, cardiovasculature, and lipid profiles, all of which are effects characteristic of estrogen. Taken together, these studies indicate that genistein can behave as an estrogen and can mediate mitogenic effects via the ER.

Estrogens have long been identified as important mitogens in the breast and thus are associated with an increase in breast cancer risk. This is evidenced by the link between reproductive factors, including ages of first menarche, first pregnancy, and menopause, and breast cancer risk. This is further supported by studies showing that elevated concentrations of estrogens in serum and urine are associated with increased postmenopausal breast cancer risk. Additionally, estrogens induce mitogenic effects in both in vitro and in vivo models of breast cancer. The role of estrogen in this disease is supported by the fact that removal of ovarian estrogens by bilateral ovariectomy or use of tamoxifen (which blocks ER in the mammary gland) significantly reduces breast cancer risk. Because estrogen exposure presumably increases breast cancer risk, evidence showing that genistein acts in an estrogenic fashion is puzzling in light of the in vitro reports of genistein as an anticancer agent. To address studies that demonstrate the protective effects of genistein in in vitro and in vivo breast cancer models, it is important to determine whether genistein has antiestrogenic properties as well.

Reference Link: Click for more Details


specifications and supplying conditions:

Content Standardized: Soy Bean isoflavones 40%HPLC Genistein 80~98%HPLC Daidzein 98%HPLC
Serie Code: S33.M05.
Expiration Date: 18~24Months in Good Condition
Storage Stock: Bulk in Stock
Pricing Terms: C&F;CIF;DDU;DDP.
Delivery Arrange: Soonest on the Day Confirmed
Appearance Showing: Yellow Fine Powder to White Powder
Extracts State: Fine Crystal Powder
Mesh Size: 100% Pass 80 Mesh Screen
Color: Yello or light Yellow(Soy Isoflavones)or Similar Light Yellow White to White Powder(Genistein)
Odor and Smell: Charateristics
Taste Sense: Flavour with Characteristics
Bulk Density: 0.40~0.50g/ml.

Reference Link: Click for more Details